Zur Kurzanzeige

2012-01-12Zeitschriftenartikel DOI: 10.25646/971
Influenza A(H1N1)pdm09 antibodies after pandemic and trivalent seasonal influenza vaccination as well as natural infection in November 2010 in Hamburg, Germany
dc.contributor.authorCramer, J. P.
dc.contributor.authorMac, T.
dc.contributor.authorHogan, B.
dc.contributor.authorStauga, S.
dc.contributor.authorEberhardt, S.
dc.contributor.authorWichmann, Ole
dc.contributor.authorMertens, Thomas
dc.contributor.authorBurchard, G. D.
dc.date.accessioned2018-05-07T15:07:48Z
dc.date.available2018-05-07T15:07:48Z
dc.date.created2012-01-17
dc.date.issued2012-01-12none
dc.identifier.otherhttp://edoc.rki.de/oa/articles/reVH5FgPr2aY/PDF/24ogJij5ge392.pdf
dc.identifier.urihttp://edoc.rki.de/176904/1046
dc.description.abstractThe 2009 influenza pandemic has introduced the new re-assorted influenza A(H1N1)pdm09 virus which recirculated during the 2010/11 influenza season. Before that season, it was possible to acquire protective immunity either by pandemic or seasonal influenza vaccination against influenza A(H1N1)pdm09 or by natural infection. To obtain data on vaccination coverage and antibody levels in a reference population and to calculate whether or not the herd immunity threshold (HIT, calculated as 33% given an R0 of 1.5) was reached at the beginning of the 2010/11 season we performed a seroprevalence study in November 2010 in Hamburg, Germany. Antibody titres were assessed applying a haemagglutination inhibition test. Vaccination coverage was very low: 14% for pandemic and 11% for seasonal 2010/11 vaccinations. Even in those with underlying risk factors, vaccination coverage was not much higher: 17% for both vaccines. Serological analysis revealed antibody titres of ≥1:10 in 135 of 352 (38%) and of ≥1:40 in 61 of 352 study participants (17%). Specific antibodies were measurable in 26% of those without history of vaccination or natural infection, indicating a high proportion of subclinical and mild influenza disease. Nevertheless, the HIT was not reached, leaving the majority of the population susceptible to influenza A(H1N1)pdm09 and its potential complications.eng
dc.language.isoeng
dc.publisherRobert Koch-Institut, Infektionsepidemiologie
dc.subjectAdolescenteng
dc.subjectHumanseng
dc.subjectGermany/epidemiologyeng
dc.subjectMaleeng
dc.subjectMiddle Agedeng
dc.subjectPrevalenceeng
dc.subjectRisk Factorseng
dc.subjectAdulteng
dc.subjectSeroepidemiologic Studieseng
dc.subjectCross-Sectional Studieseng
dc.subjectQuestionnaireseng
dc.subjectAgedeng
dc.subjectInfluenza A Viruseng
dc.subjectSeasonseng
dc.subjectVaccinationeng
dc.subjectYoung Adulteng
dc.subjectHemagglutination Inhibition Testseng
dc.subjectAntibodies Viral/bloodeng
dc.subjectInfluenza Human/epidemiologyeng
dc.subjectPandemicseng
dc.subjectInfluenza Human/prevention & controleng
dc.subjectInfluenza Vaccines/immunologyeng
dc.subjectH1N1 Subtype/immunologyeng
dc.subjectInfluenza Vaccines/administration & dosageeng
dc.subject.ddc610 Medizin
dc.titleInfluenza A(H1N1)pdm09 antibodies after pandemic and trivalent seasonal influenza vaccination as well as natural infection in November 2010 in Hamburg, Germany
dc.typeperiodicalPart
dc.identifier.urnurn:nbn:de:0257-10017417
dc.identifier.doihttp://dx.doi.org/10.25646/971
local.edoc.container-titleEuroSurveillance
local.edoc.fp-subtypeArtikel
local.edoc.type-nameZeitschriftenartikel
local.edoc.container-typeperiodical
local.edoc.container-type-nameZeitschrift
local.edoc.container-urlhttp://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20052
local.edoc.container-publisher-nameECDC
local.edoc.container-volume17
local.edoc.container-issue2
local.edoc.container-year2012

Zur Kurzanzeige